Wegovy vs Mounjaro in New Zealand: What to Know in 2026
- Canaan Aumua
- Sep 9, 2025
- 2 min read
Updated: Feb 20
Last updated: February 2026
Medicines like Wegovy, Ozempic, Mounjaro, Zepbound, Saxenda and Victoza are part of a new generation of treatments for weight loss and type 2 diabetes.
If you’re in New Zealand, you might be wondering:
Which GLP-1 medicines are available now — and how do they compare?
Here’s what’s currently available in NZ in 2026.
GLP-1 Medicines in New Zealand (2026)
Company | Medication | Main Use | Dosing | Availability in NZ (2025) | Notes |
Novo Nordisk | Wegovy (semaglutide) | Weight loss | Weekly injection | Available privately (not funded) | Strong weight loss; proven cardiovascular benefit |
Ozempic (semaglutide) | Type 2 diabetes (sometimes off-label for weight loss) | Weekly injection | Not available | Same ingredient as Wegovy but lower doses | |
Saxenda (liraglutide) | Weight loss | Daily injection | Available privately (not funded) | Older GLP-1; less effective than semaglutide | |
Victoza (liraglutide) | Type 2 diabetes | Daily injection | Available - special criteria funding applies | Diabetes indication only | |
Eli Lilly | Mounjaro (tirzepatide) | Type 2 diabetes & weight management | Weekly injection | Available privately (not funded) | Dual GIP + GLP-1; greater average weight loss in trials |
Zepbound (tirzepatide) | Weight loss; sleep apnoea in obesity | Weekly injection | Not yet available | Same medicine as Mounjaro, branded for weight loss | |
Trulicity (dulaglutide) | Type 2 diabetes | Weekly injection | Available - special criteria funding applies | Established GLP-1 option for diabetes; not indicated for weight loss |
Wegovy vs Mounjaro: Which Is Better?
Now that both are available in NZ, this is one of the most common questions.
Weight loss results
In clinical trials, tirzepatide (Mounjaro) has demonstrated greater average weight loss compared to semaglutide (Wegovy).
Cardiovascular data
Wegovy has robust data showing reduction in heart attack and stroke risk in people with cardiovascular disease.
Mechanism
Wegovy → GLP-1 only
Mounjaro → GLP-1 + GIP
Dosing & Cost
Wegovy pricing is usually consistent across strengths in NZ, while Mounjaro costs can increase at higher doses.
Bottom line
There is no universal “better” medication. The right option depends on:
Medical history
Weight-loss goals
Side-effect tolerance
Budget considerations
A GP assessment ensures the safest choice.
What’s Available in New Zealand Right Now?
For Weight Loss (Private Prescription)
Wegovy
Mounjaro
Saxenda
For Type 2 Diabetes
Victoza (special criteria funding applies)
Trulicity (special criteria funding applies)
Mounjaro
Ozempic and Zepbound are not currently available in NZ.
Key Insights
Wegovy and Mounjaro are now the leading weekly weight-loss options in NZ.
Saxenda remains available but is generally less effective.
Mounjaro has shown greater average weight loss in trials, but individual response varies.
None of these medicines are currently Pharmac-funded for weight loss.
How Pocket Lab Can Help
At Pocket Lab, our NZ-registered GPs specialise in medically supervised weight management.
We provide:
GP-led consultations
Dose titration and side-effect management
Structured follow-up
Access to Wegovy and Mounjaro
Ongoing monitoring
As a Health New Zealand–accredited online GP provider with a 5.0 rating from 490+ Google reviews, we focus on safe, sustainable, evidence-based care — not one-off prescriptions.
